Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Dise

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,795	232 Pages	Transparency Market Research Pvt. Ltd.	May, 2022	TNPR17326568

Best Price Guarantee
Price	from $5,795
Length	232 Pages
Publisher	Transparency Market Research Pvt. Ltd.
Published Date	May, 2022
SKU	TNPR17326568

Intravenous Immunoglobulin Market (Indication: Chronic Inflammatory Demyelinating Polyneuropathy, Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura, Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy, Kawasaki Disease, Hypogammaglobulinemia, Chronic Lymphocytic Leukemia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Companies Mentioned

Baxalta Incorporated
Biotest AG
China Biologic Products, Inc.
CSL Behring LLC
Grifols S.A.
Kedrion S.p.A.
LFB Biomedicaments S.A.
Octapharma AG
Sanquin Plasma Products B.V."

Countries

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Forecast Year (first) - 2022

Forecast Year (last) - 2031

Forecast Year ( first) Value - 11.2

Forecast Year (last) Value - 20.5

CAGR % - 0.073

Currency - US$ Bn

1. Preface: 1.1. Report Scope and Market Segmentation; 1.2. Research Highlights
2. Assumptions and Research Methodology: 2.1. Assumptions; 2.2. Research Methodology
3. Executive Summary: 3.1. Global Intravenous Immunoglobulin (IVIG): Market Snapshot; 3.2. Market Share Analysis, by Region, 2017; 3.3. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map
4. Market Overview: 4.1. Indication Overview; 4.2. Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments; 4.3. Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators
5. Market Dynamics: 5.1. Drivers and Restraints Snapshot Analysis; 5.2. Drivers; 5.2.1. Rise in prevalence of autoimmune disorders; 5.2.2. Increase in global geriatric population; 5.2.3. Growing usage in off-label indications; 5.2.4. Improved technology for production and purification methods; 5.2.5. Favorable government initiatives and approvals; 5.2.6. Increase in health care spending & improving health care infrastructure; 5.2.7. Rise in incidence of hematological, neurological disorders; 5.3. Restraints; 5.3.1. High cost of treatment; 5.3.2. Chronic side effects; 5.3.3. Supply demand gaps; 5.3.4. Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications; 5.4. Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis; 5.5. Opportunities; 5.5.1. Application in newer indications; 5.5.2. Increasing global plasma yield to offer significant opportunities to new entrants; 5.6. Key Trends; 5.7. Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2017–2031; 5.8. Value Chain Analysis; 5.9. Global Intravenous Immunoglobulin (IVIG) Market Outlook
6. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication: 6.1. Key Findings; 6.2. Introduction; 6.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication; 6.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication; 6.4.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 6.4.2. Primary Humoral Immunodeficiency; 6.4.3. Idiopathic Thrombocytopenic Purpura (ITP); 6.4.4. Guillain-Barre Syndrome; 6.4.5. Myasthenia Gravis; 6.4.6. Multifocal Motor Neuropathy (MMN); 6.4.7. Kawasaki Disease; 6.4.8. Hypogammaglobulinemia; 6.4.9. Chronic Lymphocytic Leukemia; 6.4.10. Others; 6.5. Market Attractiveness Analysis, by Indication; 6.6. Key Trends
7. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user: 7.1. Key Findings; 7.2. Introduction; 7.3. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user; 7.4. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user; 7.4.1. Hospitals; 7.4.2. Clinics; 7.4.3. Home Care; 7.5. Market Attractiveness Analysis, by End-user; 7.6. Key Trends
8. Global Intravenous Immunoglobulin (IVIG) Market Analysis, by Region: 8.1. Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country; 8.2. Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region; 8.3. Intravenous Immunoglobulin (IVIG) Market Forecast, by Region; 8.4. Market Attractiveness Analysis, by Region
9. North America Intravenous Immunoglobulin (IVIG) Market Analysis: 9.1. Key Findings; 9.2. Market Overview; 9.3. Market Analysis, by Indication; 9.3.1. Market Value Share Analysis, by Indication; 9.3.2. Market Size (US$ Mn) Forecast, by Indication; 9.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 9.3.2.2. Primary Humoral Immunodeficiency; 9.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP); 9.3.2.4. Guillain-Barre Syndrome; 9.3.2.5. Myasthenia Gravis; 9.3.2.6. Multifocal Motor Neuropathy (MMN); 9.3.2.7. Kawasaki Disease; 9.3.2.8. Hypogammaglobulinemia; 9.3.2.9. Chronic Lymphocytic Leukemia; 9.3.2.10. Others; 9.4. Market Analysis, by End-user; 9.4.1. Market Value Share Analysis, by End-user; 9.4.2. Market Size (US$ Mn) Forecast, by End-user; 9.4.2.1. Hospitals; 9.4.2.2. Clinics; 9.4.2.3. Home Care; 9.5. Market Analysis, by Country; 9.5.1. Market Value Share Analysis, by Country; 9.5.2. Market Size (US$ Mn) Forecast, by Country, 2017–2031; 9.5.2.1. U.S.; 9.5.2.2. Canada; 9.6. Market Attractiveness Analysis; 9.6.1. By Indication; 9.6.2. By End-user; 9.6.3. By Country; 9.7. U.S. Intravenous Immunoglobulin (IVIG) Market Analysis; 9.7.1. Market Size (US$ Mn) Forecast, by Indication; 9.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 9.7.1.2. Primary Humoral Immunodeficiency; 9.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 9.7.1.4. Guillain-Barre Syndrome; 9.7.1.5. Myasthenia Gravis; 9.7.1.6. Multifocal Motor Neuropathy (MMN); 9.7.1.7. Kawasaki Disease; 9.7.1.8. Hypogammaglobulinemia; 9.7.1.9. Chronic Lymphocytic Leukemia; 9.7.1.10. Others; 9.7.2. Market Size (US$ Mn) Forecast, by End-user; 9.7.2.1. Hospitals; 9.7.2.2. Clinics; 9.7.2.3. Home Care Settings; 9.8. Canada Intravenous Immunoglobulin (IVIG) Market Analysis; 9.8.1. Market Size (US$ Mn) Forecast, by Indication; 9.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 9.8.1.2. Primary Humoral Immunodeficiency; 9.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 9.8.1.4. Guillain-Barre Syndrome; 9.8.1.5. Myasthenia Gravis; 9.8.1.6. Multifocal Motor Neuropathy (MMN); 9.8.1.7. Kawasaki Disease; 9.8.1.8. Hypogammaglobulinemia; 9.8.1.9. Chronic Lymphocytic Leukemia; 9.8.1.10. Others; 9.8.2. Market Size (US$ Mn) Forecast, by End-user; 9.8.2.1. Hospitals; 9.8.2.2. Clinics; 9.8.2.3. Home Care Settings
10. Europe Intravenous Immunoglobulin (IVIG) Market Analysis: 10.1. Key Findings; 10.2. Market Overview; 10.3. Market Analysis, by Indication; 10.3.1. Market Value Share Analysis, by Indication; 10.3.2. Market Size (US$ Mn) Forecast, by Indication; 10.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.3.2.2. Primary Humoral Immunodeficiency; 10.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.3.2.4. Guillain-Barre Syndrome; 10.3.2.5. Myasthenia Gravis; 10.3.2.6. Multifocal Motor Neuropathy (MMN); 10.3.2.7. Kawasaki Disease; 10.3.2.8. Hypogammaglobulinemia; 10.3.2.9. Chronic Lymphocytic Leukemia; 10.3.2.10. Others; 10.4. Market Analysis, by End-user; 10.4.1. Market Value Share Analysis, by End-user; 10.4.2. Market Size (US$ Mn) Forecast, by End-user; 10.4.2.1. Hospitals; 10.4.2.2. Clinics; 10.4.2.3. Home Care; 10.5. Market Analysis, by Country/Sub-region; 10.5.1. Market Value Share Analysis, by Country/Sub-region; 10.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031; 10.5.2.1. U.K.; 10.5.2.2. Germany; 10.5.2.3. France; 10.5.2.4. Spain; 10.5.2.5. Italy; 10.5.2.6. Rest of Europe; 10.6. Market Attractiveness Analysis; 10.6.1. By Indication; 10.6.2. By End-user; 10.6.3. By Country/Sub-region; 10.7. U.K. Intravenous Immunoglobulin (IVIG) Market Analysis; 10.7.1. Market Size (US$ Mn) Forecast, by Indication; 10.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.7.1.2. Primary Humoral Immunodeficiency; 10.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.7.1.4. Guillain-Barre Syndrome; 10.7.1.5. Myasthenia Gravis; 10.7.1.6. Multifocal Motor Neuropathy (MMN); 10.7.1.7. Kawasaki Disease; 10.7.1.8. Hypogammaglobulinemia; 10.7.1.9. Chronic Lymphocytic Leukemia; 10.7.1.10. Others; 10.7.2. Market Size (US$ Mn) Forecast, by End-user; 10.7.2.1. Hospitals; 10.7.2.2. Clinics; 10.7.2.3. Home Care Settings; 10.8. Germany Intravenous Immunoglobulin (IVIG) Market Analysis; 10.8.1. Market Size (US$ Mn) Forecast, by Indication; 10.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.8.1.2. Primary Humoral Immunodeficiency; 10.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.8.1.4. Guillain-Barre Syndrome; 10.8.1.5. Myasthenia Gravis; 10.8.1.6. Multifocal Motor Neuropathy (MMN); 10.8.1.7. Kawasaki Disease; 10.8.1.8. Hypogammaglobulinemia; 10.8.1.9. Chronic Lymphocytic Leukemia; 10.8.1.10. Others; 10.8.2. Market Size (US$ Mn) Forecast, by End-user; 10.8.2.1. Hospitals; 10.8.2.2. Clinics; 10.8.2.3. Home Care Settings; 10.9. France Intravenous Immunoglobulin (IVIG) Market Analysis; 10.9.1. Market Size (US$ Mn) Forecast, by Indication; 10.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.9.1.2. Primary Humoral Immunodeficiency; 10.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.9.1.4. Guillain-Barre Syndrome; 10.9.1.5. Myasthenia Gravis; 10.9.1.6. Multifocal Motor Neuropathy (MMN); 10.9.1.7. Kawasaki Disease; 10.9.1.8. Hypogammaglobulinemia; 10.9.1.9. Chronic Lymphocytic Leukemia; 10.9.1.10. Others; 10.9.2. Market Size (US$ Mn) Forecast, by End-user; 10.9.2.1. Hospitals; 10.9.2.2. Clinics; 10.9.2.3. Home Care Settings; 10.10. Spain Intravenous Immunoglobulin (IVIG) Market Analysis; 10.10.1. Market Size (US$ Mn) Forecast, by Indication; 10.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.10.1.2. Primary Humoral Immunodeficiency; 10.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.10.1.4. Guillain-Barre Syndrome; 10.10.1.5. Myasthenia Gravis; 10.10.1.6. Multifocal Motor Neuropathy (MMN); 10.10.1.7. Kawasaki Disease; 10.10.1.8. Hypogammaglobulinemia; 10.10.1.9. Chronic Lymphocytic Leukemia; 10.10.1.10. Others; 10.10.2. Market Size (US$ Mn) Forecast, by End-user; 10.10.2.1. Hospitals; 10.10.2.2. Clinics; 10.10.2.3. Home Care Settings; 10.11. Italy Intravenous Immunoglobulin (IVIG) Market Analysis; 10.11.1. Market Size (US$ Mn) Forecast, by Indication; 10.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.11.1.2. Primary Humoral Immunodeficiency; 10.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.11.1.4. Guillain-Barre Syndrome; 10.11.1.5. Myasthenia Gravis; 10.11.1.6. Multifocal Motor Neuropathy (MMN); 10.11.1.7. Kawasaki Disease; 10.11.1.8. Hypogammaglobulinemia; 10.11.1.9. Chronic Lymphocytic Leukemia; 10.11.1.10. Others; 10.11.2. Market Size (US$ Mn) Forecast, by End-user; 10.11.2.1. Hospitals; 10.11.2.2. Clinics; 10.11.2.3. Home Care Settings; 10.12. Rest of Europe Intravenous Immunoglobulin (IVIG) Market Analysis; 10.12.1. Market Size (US$ Mn) Forecast, by Indication; 10.12.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 10.12.1.2. Primary Humoral Immunodeficiency; 10.12.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 10.12.1.4. Guillain-Barre Syndrome; 10.12.1.5. Myasthenia Gravis; 10.12.1.6. Multifocal Motor Neuropathy (MMN); 10.12.1.7. Kawasaki Disease; 10.12.1.8. Hypogammaglobulinemia; 10.12.1.9. Chronic Lymphocytic Leukemia; 10.12.1.10. Others; 10.12.2. Market Size (US$ Mn) Forecast, by End-user; 10.12.2.1. Hospitals; 10.12.2.2. Clinics; 10.12.2.3. Home Care Settings
11. Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis: 11.1. Key Findings; 11.2. Market Overview; 11.3. Market Analysis, by Indication; 11.3.1. Market Value Share Analysis, by Indication; 11.3.2. Market Size (US$ Mn) Forecast, by Indication; 11.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 11.3.2.2. Primary Humoral Immunodeficiency; 11.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP); 11.3.2.4. Guillain-Barre Syndrome; 11.3.2.5. Myasthenia Gravis; 11.3.2.6. Multifocal Motor Neuropathy (MMN); 11.3.2.7. Kawasaki Disease; 11.3.2.8. Hypogammaglobulinemia; 11.3.2.9. Chronic Lymphocytic Leukemia; 11.3.2.10. Others; 11.4. Market Analysis, by End-user; 11.4.1. Market Value Share Analysis, by End-user; 11.4.2. Market Size (US$ Mn) Forecast, by End-user; 11.4.2.1. Hospitals; 11.4.2.2. Clinics; 11.4.2.3. Home Care; 11.5. Market Analysis, by Country/Sub-region; 11.5.1. Market Value Share Analysis, by Country/Sub-region; 11.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031; 11.5.2.1. China; 11.5.2.2. Japan; 11.5.2.3. Australia; 11.5.2.4. India; 11.5.2.5. Rest of Asia Pacific; 11.6. Market Attractiveness Analysis; 11.6.1. By Indication; 11.6.2. By End-user; 11.6.3. By Country/Sub-region; 11.7. China Intravenous Immunoglobulin (IVIG) Market Analysis; 11.7.1. Market Size (US$ Mn) Forecast, by Indication; 11.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 11.7.1.2. Primary Humoral Immunodeficiency; 11.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 11.7.1.4. Guillain-Barre Syndrome; 11.7.1.5. Myasthenia Gravis; 11.7.1.6. Multifocal Motor Neuropathy (MMN); 11.7.1.7. Kawasaki Disease; 11.7.1.8. Hypogammaglobulinemia; 11.7.1.9. Chronic Lymphocytic Leukemia; 11.7.1.10. Others; 11.7.2. Market Size (US$ Mn) Forecast, by End-user; 11.7.2.1. Hospitals; 11.7.2.2. Clinics; 11.7.2.3. Home Care Settings; 11.8. Japan Intravenous Immunoglobulin (IVIG) Market Analysis; 11.8.1. Market Size (US$ Mn) Forecast, by Indication; 11.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 11.8.1.2. Primary Humoral Immunodeficiency; 11.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 11.8.1.4. Guillain-Barre Syndrome; 11.8.1.5. Myasthenia Gravis; 11.8.1.6. Multifocal Motor Neuropathy (MMN); 11.8.1.7. Kawasaki Disease; 11.8.1.8. Hypogammaglobulinemia; 11.8.1.9. Chronic Lymphocytic Leukemia; 11.8.1.10. Others; 11.8.2. Market Size (US$ Mn) Forecast, by End-user; 11.8.2.1. Hospitals; 11.8.2.2. Clinics; 11.8.2.3. Home Care Settings; 11.9. Australia Intravenous Immunoglobulin (IVIG) Market Analysis; 11.9.1. Market Size (US$ Mn) Forecast, by Indication; 11.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 11.9.1.2. Primary Humoral Immunodeficiency; 11.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 11.9.1.4. Guillain-Barre Syndrome; 11.9.1.5. Myasthenia Gravis; 11.9.1.6. Multifocal Motor Neuropathy (MMN); 11.9.1.7. Kawasaki Disease; 11.9.1.8. Hypogammaglobulinemia; 11.9.1.9. Chronic Lymphocytic Leukemia; 11.9.1.10. Others; 11.9.2. Market Size (US$ Mn) Forecast, by End-user; 11.9.2.1. Hospitals; 11.9.2.2. Clinics; 11.9.2.3. Home Care Settings; 11.10. India Intravenous Immunoglobulin (IVIG) Market Analysis; 11.10.1. Market Size (US$ Mn) Forecast, by Indication; 11.10.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 11.10.1.2. Primary Humoral Immunodeficiency; 11.10.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 11.10.1.4. Guillain-Barre Syndrome; 11.10.1.5. Myasthenia Gravis; 11.10.1.6. Multifocal Motor Neuropathy (MMN); 11.10.1.7. Kawasaki Disease; 11.10.1.8. Hypogammaglobulinemia; 11.10.1.9. Chronic Lymphocytic Leukemia; 11.10.1.10. Others; 11.10.2. Market Size (US$ Mn) Forecast, by End-user; 11.10.2.1. Hospitals; 11.10.2.2. Clinics; 11.10.2.3. Home Care Settings; 11.11. Rest of Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis; 11.11.1. Market Size (US$ Mn) Forecast, by Indication; 11.11.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 11.11.1.2. Primary Humoral Immunodeficiency; 11.11.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 11.11.1.4. Guillain-Barre Syndrome; 11.11.1.5. Myasthenia Gravis; 11.11.1.6. Multifocal Motor Neuropathy (MMN); 11.11.1.7. Kawasaki Disease; 11.11.1.8. Hypogammaglobulinemia; 11.11.1.9. Chronic Lymphocytic Leukemia; 11.11.1.10. Others; 11.11.2. Market Size (US$ Mn) Forecast, by End-user; 11.11.2.1. Hospitals; 11.11.2.2. Clinics; 11.11.2.3. Home Care Settings
12. Latin America Intravenous Immunoglobulin (IVIG) Market Analysis: 12.1. Key Findings; 12.2. Market Overview; 12.3. Market Analysis, by Indication; 12.3.1. Market Value Share Analysis, by Indication; 12.3.2. Market Size (US$ Mn) Forecast, by Indication; 12.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 12.3.2.2. Primary Humoral Immunodeficiency; 12.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP); 12.3.2.4. Guillain-Barre Syndrome; 12.3.2.5. Myasthenia Gravis; 12.3.2.6. Multifocal Motor Neuropathy (MMN); 12.3.2.7. Kawasaki Disease; 12.3.2.8. Hypogammaglobulinemia; 12.3.2.9. Chronic Lymphocytic Leukemia; 12.3.2.10. Others; 12.4. Market Analysis, by End-user; 12.4.1. Market Value Share Analysis, by End-user; 12.4.2. Market Size (US$ Mn) Forecast, by End-user; 12.4.2.1. Hospitals; 12.4.2.2. Clinics; 12.4.2.3. Home Care; 12.5. Market Analysis, by Country/Sub-region; 12.5.1. Market Value Share Analysis, by Country/Sub-region; 12.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031; 12.5.2.1. Brazil; 12.5.2.2. Mexico; 12.5.2.3. Rest of Latin America; 12.6. Market Attractiveness Analysis; 12.6.1. By Indication; 12.6.2. By End-user; 12.6.3. By Country/Sub-region; 12.7. Brazil Intravenous Immunoglobulin (IVIG) Market Analysis; 12.7.1. Market Size (US$ Mn) Forecast, by Indication; 12.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 12.7.1.2. Primary Humoral Immunodeficiency; 12.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 12.7.1.4. Guillain-Barre Syndrome; 12.7.1.5. Myasthenia Gravis; 12.7.1.6. Multifocal Motor Neuropathy (MMN); 12.7.1.7. Kawasaki Disease; 12.7.1.8. Hypogammaglobulinemia; 12.7.1.9. Chronic Lymphocytic Leukemia; 12.7.1.10. Others; 12.7.2. Market Size (US$ Mn) Forecast, by End-user; 12.7.2.1. Hospitals; 12.7.2.2. Clinics; 12.7.2.3. Home Care Settings; 12.8. Mexico Intravenous Immunoglobulin (IVIG) Market Analysis; 12.8.1. Market Size (US$ Mn) Forecast, by Indication; 12.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 12.8.1.2. Primary Humoral Immunodeficiency; 12.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 12.8.1.4. Guillain-Barre Syndrome; 12.8.1.5. Myasthenia Gravis; 12.8.1.6. Multifocal Motor Neuropathy (MMN); 12.8.1.7. Kawasaki Disease; 12.8.1.8. Hypogammaglobulinemia; 12.8.1.9. Chronic Lymphocytic Leukemia; 12.8.1.10. Others; 12.8.2. Market Size (US$ Mn) Forecast, by End-user; 12.8.2.1. Hospitals; 12.8.2.2. Clinics; 12.8.2.3. Home Care Settings; 12.9. Rest of Latin America Intravenous Immunoglobulin (IVIG) Market Analysis; 12.9.1. Market Size (US$ Mn) Forecast, by Indication; 12.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 12.9.1.2. Primary Humoral Immunodeficiency; 12.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 12.9.1.4. Guillain-Barre Syndrome; 12.9.1.5. Myasthenia Gravis; 12.9.1.6. Multifocal Motor Neuropathy (MMN); 12.9.1.7. Kawasaki Disease; 12.9.1.8. Hypogammaglobulinemia; 12.9.1.9. Chronic Lymphocytic Leukemia; 12.9.1.10. Others; 12.9.2. Market Size (US$ Mn) Forecast, by End-user; 12.9.2.1. Hospitals; 12.9.2.2. Clinics; 12.9.2.3. Home Care Settings
13. Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis: 13.1. Key Findings; 13.2. Market Overview; 13.3. Market Analysis, by Indication; 13.3.1. Market Value Share Analysis, by Indication; 13.3.2. Market Size (US$ Mn) Forecast, by Indication; 13.3.2.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 13.3.2.2. Primary Humoral Immunodeficiency; 13.3.2.3. Idiopathic Thrombocytopenic Purpura (ITP); 13.3.2.4. Guillain-Barre Syndrome; 13.3.2.5. Myasthenia Gravis; 13.3.2.6. Multifocal Motor Neuropathy (MMN); 13.3.2.7. Kawasaki Disease; 13.3.2.8. Hypogammaglobulinemia; 13.3.2.9. Chronic Lymphocytic Leukemia; 13.3.2.10. Others; 13.4. Market Analysis, by End-user; 13.4.1. Market Value Share Analysis, by End-user; 13.4.2. Market Size (US$ Mn) Forecast, by End-user; 13.4.2.1. Hospitals; 13.4.2.2. Clinics; 13.4.2.3. Home Care; 13.5. Market Analysis, by Country/Sub-region; 13.5.1. Market Value Share Analysis, by Country/Sub-region; 13.5.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031; 13.5.2.1. GCC Countries; 13.5.2.2. South Africa; 13.5.2.3. Rest of Middle East & Africa; 13.6. Market Attractiveness Analysis; 13.6.1. By Indication; 13.6.2. By End-user; 13.6.3. By Country/Sub-region; 13.7. GCC Countries Intravenous Immunoglobulin (IVIG) Market Analysis; 13.7.1. Market Size (US$ Mn) Forecast, by Indication; 13.7.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 13.7.1.2. Primary Humoral Immunodeficiency; 13.7.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 13.7.1.4. Guillain-Barre Syndrome; 13.7.1.5. Myasthenia Gravis; 13.7.1.6. Multifocal Motor Neuropathy (MMN); 13.7.1.7. Kawasaki Disease; 13.7.1.8. Hypogammaglobulinemia; 13.7.1.9. Chronic Lymphocytic Leukemia; 13.7.1.10. Others; 13.7.2. Market Size (US$ Mn) Forecast, by End-user; 13.7.2.1. Hospitals; 13.7.2.2. Clinics; 13.7.2.3. Home Care Settings; 13.8. South Africa Intravenous Immunoglobulin (IVIG) Market Analysis; 13.8.1. Market Size (US$ Mn) Forecast, by Indication; 13.8.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 13.8.1.2. Primary Humoral Immunodeficiency; 13.8.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 13.8.1.4. Guillain-Barre Syndrome; 13.8.1.5. Myasthenia Gravis; 13.8.1.6. Multifocal Motor Neuropathy (MMN); 13.8.1.7. Kawasaki Disease; 13.8.1.8. Hypogammaglobulinemia; 13.8.1.9. Chronic Lymphocytic Leukemia; 13.8.1.10. Others; 13.8.2. Market Size (US$ Mn) Forecast, by End-user; 13.8.2.1. Hospitals; 13.8.2.2. Clinics; 13.8.2.3. Home Care Settings; 13.9. Rest of Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis; 13.9.1. Market Size (US$ Mn) Forecast, by Indication; 13.9.1.1. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP); 13.9.1.2. Primary Humoral Immunodeficiency; 13.9.1.3. Idiopathic Thrombocytopenic Purpura (ITP); 13.9.1.4. Guillain-Barre Syndrome; 13.9.1.5. Myasthenia Gravis; 13.9.1.6. Multifocal Motor Neuropathy (MMN); 13.9.1.7. Kawasaki Disease; 13.9.1.8. Hypogammaglobulinemia; 13.9.1.9. Chronic Lymphocytic Leukemia; 13.9.1.10. Others; 13.9.2. Market Size (US$ Mn) Forecast, by End-user; 13.9.2.1. Hospitals; 13.9.2.2. Clinics; 13.9.2.3. Home Care Settings
14. Company Profiles: 14.1. Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2021); 14.2. Competition Matrix; 14.3. Company Profiles; 14.3.1. Baxalta Incorporated; 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.1.2. Financial Overview; 14.3.1.3. Product Portfolio; 14.3.1.4. SWOT Analysis; 14.3.1.5. Strategic Overview; 14.3.2. Biotest AG; 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.2.2. Financial Overview; 14.3.2.3. Product Portfolio; 14.3.2.4. SWOT Analysis; 14.3.2.5. Strategic Overview; 14.3.3. China Biologic Products, Inc.; 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.3.2. Financial Overview; 14.3.3.3. Product Portfolio; 14.3.3.4. SWOT Analysis; 14.3.3.5. Strategic Overview; 14.3.4. CSL Behring LLC; 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.4.2. Financial Overview; 14.3.4.3. Product Portfolio; 14.3.4.4. SWOT Analysis; 14.3.4.5. Strategic Overview; 14.3.5. Grifols S.A.; 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.5.2. Financial Overview; 14.3.5.3. Product Portfolio; 14.3.5.4. SWOT Analysis; 14.3.5.5. Strategic Overview; 14.3.6. Kedrion S.p.A.; 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.6.2. Financial Overview; 14.3.6.3. Product Portfolio; 14.3.6.4. SWOT Analysis; 14.3.6.5. Strategic Overview; 14.3.7. LFB Biomedicaments S.A.; 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.7.2. Financial Overview; 14.3.7.3. Product Portfolio; 14.3.7.4. SWOT Analysis; 14.3.7.5. Strategic Overview; 14.3.8. Octapharma AG; 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.8.2. Financial Overview; 14.3.8.3. Product Portfolio; 14.3.8.4. SWOT Analysis; 14.3.8.5. Strategic Overview; 14.3.9. Sanquin Plasma Products B.V.; 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength); 14.3.9.2. Financial Overview; 14.3.9.3. Product Portfolio; 14.3.9.4. SWOT Analysis; 14.3.9.5. Strategic Overview